Razoxane (ICRF 159) is an antiangiogenic topoisomerase II inhibitor, can be used for the research of renal cell carcinoma (RCC).In Vitro: Razoxane (30 mg/kg; i.p.) exhibits antimetastatic effects in a rat osteosarcoma model.In Vivo: Early treatment with Razoxane (30 mg/kg i.p. from day -2 to +14) shows a greater inhibition of pulmonary metastases than later treatment (30 mg/kg i.p. from day +14 to +28 after transplantation)[2].